On February 6 AstraZeneca released its full quarter and full year results 2013 where it stood clear that the company expects another 550 layoffs due to savings.
Of the 550 jobs, 168 of them will be cut off as the R&D unit in Avishkar (Bangalore, India) is closed down. The remaining 400 posts will be cut from the company’s global IT unit. Like the 5,050 cuts previously announced, the additional 550 will come over the next few years and will be wrapped up by 2016, the company said.
The U.S. Food and Drug Administration (FDA) has conditionally approved the Swedish pharmaceutical company’s product Paccal. Paccal Vet-CA1 is the first veterinary drug to utilize paclitaxel, a frequently used chemotherapeutics for the treatment of a wide range of cancers in humans. Paccal Vet-CA1 is specifically formulated for use in dogs for the treatment…
AstraZeneca and Bristol-Myers Squibb treatment for type 2 diabetes Xigduo has been granted Marketing Authorization by the European Commission. Xigduo, which has the trade name Forxiga, combines dapagliflozin, a selective and reversible inhibitor of SGLT2 with metformin hydrochloride, two anti-hyperglycaemic products with complementary mechanisms of action to improve glycaemic control. This is the…
A multi-billion kroner agreement on a new pain-relief medication has been signed between the Norwegian innovation company, Inven2, and the pharmaceuticals giant, Merck. Public funding has played an important role in the Norwegian researchers’ success. The agreement confirms the vast potential of Norwegian health research. There are many outstanding researchers…
Orexo has announced that Boehringer Ingelheim has decided to return the OX-MPI project to Orexo. The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Since 2005, Boehringer Ingelheim has been responsible for all research and development within the project. Orexo will evaluate the…
